Drug Profile
Ponesimod - Johnson & Johnson Innovative Medicine
Alternative Names: ACT-128800; Compound 8bo - Actelion; PONVORY; R-3477; RG 3477Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Actelion Pharmaceuticals; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- No development reported Graft-versus-host disease
- Discontinued Plaque psoriasis
Most Recent Events
- 26 Mar 2024 Ponesimod licensed to Juvise Pharmaceuticals worldwide (excluding the USA and Canada)
- 31 Jan 2024 US Patent and Trademark Office (USPTO) issues a notice of allowance for ponesimod for Multiple sclerosis
- 16 Jan 2024 Actelion completes in the OPTIMUM-LT phase III trial for Multiple sclerosis in Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Turkey, Ukraine and United Kingdom (PO) (NCT03232073)